CDX DIAGNOSTICS OF SUFFERN EXPANDS WITH TWO NEW KEY LEADERSHIP APPOINTMENTS. COMPANY POISED FOR GROWTH AND SETS SALES TRAJECTORY FOR 2018

An innovator in computer synthesized 3D tissue analysis for the early detection and surveillance of Barrett’s esophagus, CDx appointed Jimmy Cerveaux as Chief Financial Officer and Jerry Conway as Executive Vice President of Managed Care, respectively.

Jimmy Cerveaux brings C-level executive experience He co-founded, led and sold Unicity Eldercare, a successful 150 employee healthcare company located in NY & NJ. Mr. Cerveaux also worked for many years as an Auditor and a Mergers & Acquisitions Consultant at Ernst & Young, and as an equity analyst for a leading investment management firm in the Middle East. He is a graduate of Massachusetts Institute of Technology in Cambridge, MA.

Jerry Conway joins CDx Diagnostics as Executive Vice President of Managed Care with more than 27 years of sales and executive management experience in the routine clinical and esoteric laboratory marketplaces. His experience includes physician sales and marketing, payer contracting and reimbursement in a wide range of business environments, including Fortune 500 and start-up companies.

Mark Rutenberg, Founder and CEO of CDx Diagnostics said: “I see a bright future in 2018 for the company and team as a whole; we’re collaborating with the best minds in the GI community to help prevent their patients from developing esophageal cancer – one of the most rapidly growing and deadly cancers in the United States.

CDx Diagnostics’ mission is to provide clinicians with easily implemented, cost effective, tools to preempt cancer through enhanced detection of precancerous change. This is accomplished by a proprietary diagnostic platform that synthesizes computer imaging, artificial intelligence, molecular biology and three-dimensional cytopathology to detect precancerous change earlier and more reliably than prior methods.